Sangamo Therapeutics, Inc. (SGMO)

Sangamo Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	27.79	45.2	100.44	178.87	131.33	80.43
Short-Term Investments	-	35.8	177.19	197.68	510.09	282.05
Cash & Short-Term Investments	27.79	81	277.63	376.55	641.42	362.47
Cash Growth	-80.58%	-70.82%	-26.27%	-41.29%	76.96%	-9.41%
Accounts Receivable	0.58	0.92	3.68	6.01	5.22	36.91
Other Receivables	-	0.4	0.79	0.35	1.04	0.68
Receivables	0.58	1.33	4.47	6.36	6.26	37.59
Prepaid Expenses	11.71	12	18.22	15.86	11.99	5.41
Total Current Assets	40.08	94.33	300.33	398.77	659.67	405.47
Property, Plant & Equipment	39.29	52.87	125.53	124.7	112.37	107.22
Long-Term Investments	-	-	29.85	88.17	50.53	21.83
Goodwill	-	-	37.55	39.7	42.8	39.27
Other Intangible Assets	-	-	50.73	53.76	58.13	53.16
Long-Term Deferred Tax Assets	-	-	1.12	1.06	0.47	-
Other Long-Term Assets	13.65	18.13	17.41	15.76	14.58	10.57
Total Assets	93.01	165.32	562.51	721.92	938.55	637.52
Accounts Payable	17.59	15.26	22.42	9.76	12.55	6.67
Accrued Expenses	16.37	16.15	33.39	28.39	30.66	21.28
Current Portion of Leases	-	4.59	4.12	4.03	3.69	3.21
Current Unearned Revenue	-	-	51.78	85.71	91.64	38.71
Other Current Liabilities	5.05	11.73	-	-	5	-
Total Current Liabilities	39.01	47.73	111.71	127.89	143.55	69.87
Long-Term Leases	29.1	33.52	38.99	44.06	38.4	41.19
Long-Term Unearned Revenue	-	-	109.38	166.78	245.05	81.43
Long-Term Deferred Tax Liabilities	-	-	6.27	6.65	7.19	6.57
Other Long-Term Liabilities	1.22	1.19	1.21	1.22	7.01	5.71
Total Liabilities	69.32	82.43	267.55	346.58	441.18	204.78
Common Stock	2.08	1.78	1.67	1.46	1.42	1.16
Additional Paid-In Capital	1,519	1,492	1,450	1,334	1,269	1,091
Retained Earnings	-1,492	-1,406	-1,149	-956.27	-777.98	-656.99
Comprehensive Income & Other	-5.88	-4.6	-8.4	-3.99	5.42	-2.45
Total Common Equity	23.69	82.89	294.96	375.34	498.23	432.55
Minority Interest	-	-	-	-	-0.87	0.19
Shareholders' Equity	23.69	82.89	294.96	375.34	497.37	432.74
Total Liabilities & Equity	93.01	165.32	562.51	721.92	938.55	637.52
Total Debt	29.1	38.1	43.11	48.08	42.09	44.41
Net Cash (Debt)	-1.31	42.9	264.37	416.64	649.87	339.9
Net Cash Growth	-	-83.77%	-36.55%	-35.89%	91.19%	-15.05%
Net Cash Per Share	-0.01	0.25	1.71	2.88	4.83	3.03
Filing Date Shares Outstanding	208.22	178.91	168.48	145.97	143.25	116.02
Total Common Shares Outstanding	208.2	178.13	166.79	145.92	142.06	115.97
Working Capital	1.07	46.6	188.62	270.88	516.12	335.6
Book Value Per Share	0.11	0.47	1.77	2.57	3.51	3.73
Tangible Book Value	23.69	82.89	206.68	281.88	397.31	340.13
Tangible Book Value Per Share	0.11	0.47	1.24	1.93	2.80	2.93
Machinery	-	47.02	54.72	49.85	30.7	21.82
Construction In Progress	-	1.09	14.77	4.73	12.09	5.9
Leasehold Improvements	-	29.81	30.57	21.97	15.95	13.89

Source: S&P Capital IQ. Standard template. Financial Sources.